Rigel Q1 revenue up 26% to $58.8M, net income $8.7M; reaffirms FY2026 guidance

RIGEL PHARMACEUTICALS INC

2026-Q1 EPS reported $0.44 vs consensus $0.70 ▼ miss (-36.9%)

Q1 total revenues $58.8M (net product sales $54.9M, contract $3.9M), up 26% YoY.
Net income $8.7M ($0.44 diluted EPS) vs. $11.4M ($0.63 diluted) in Q1 2025.
TAVALISSE sales $37.3M (+31%), GAVRETO $9.6M (+7%), REZLIDHIA $8.0M (+31%).
Eli Lilly to terminate ocadusertib collaboration effective June 15, 2026.
Restructured $40M MidCap revolver; repaid $40M term loan, drew $8M on new facility.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RIGEL PHARMACEUTICALS INC reported first quarter ended March 31, 2026 results: revenue $58.8 million, net income $8.7 million of net income.

Period: first quarter ended March 31, 2026
Revenue: $58.8 million
Net income: $8.7 million of net income
Result: reported results

Exact text from the filing

of any general incorporation language in such filing. --- EX-99.1 (EX-99.1) --- Rigel Reports First Quarter 2026 Financial Results • First quarter 2026 total revenues of $58.8 million , including net product sales of $54.9 million and contract revenues from collaborations of $3.9 million • Generated $8.7 million of net income in the first quarter of 2026 • On

View on SEC.gov

Browse all earnings releases →

RIGEL PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001034842-26-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.